View Financial HealthHelixmith 배당 및 자사주 매입배당 기준 점검 0/6Helixmith 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.008%자사주 매입 수익률총 주주 수익률-0.008%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates분석 기사 • 16hWe Think Helixmith (KOSDAQ:084990) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Apr 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (₩2.6b revenue, or US$1.7m).분석 기사 • Mar 27We're Not Very Worried About Helixmith's (KOSDAQ:084990) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Helixmith ( KOSDAQ:084990...공고 • Mar 13Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South KoreaNew Risk • Sep 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Revenue is less than US$5m (₩5.0b revenue, or US$3.6m).New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (26% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change).New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₩5.1b revenue, or US$3.7m).분석 기사 • Jul 14We Think Helixmith (KOSDAQ:084990) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • Mar 18Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...공고 • Mar 13Helixmith Co., Ltd, Annual General Meeting, Mar 27, 2025Helixmith Co., Ltd, Annual General Meeting, Mar 27, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South KoreaNew Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (₩127.3b market cap, or US$89.5m).New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩140.0b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (₩3.2b revenue, or US$2.3m). Market cap is less than US$100m (₩140.0b market cap, or US$99.9m).분석 기사 • Oct 18Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...공고 • Apr 26Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in fundingOn April 25, 2024, Helixmith Co., Ltd closed the transaction.공고 • Feb 06Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in fundingHelixmith Co., Ltd announced a private placement of 936,066 common shares at a price of KRW 3,610 per share for the gross proceeds of KRW 3,379,198,260 on February 5, 2024. The transaction has been approved by the shareholders of the company and is expected to close on April 25, 2024. The transaction will include participation from new investor, Woori Bank Magongnaru Station Branch.New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Revenue is less than US$5m (₩4.4b revenue, or US$3.4m).공고 • Feb 09Helixmith Co., Ltd announced that it expects to receive KRW 9.999993078 billion in funding from CANARIABIO M Inc.Helixmith Co., Ltd announced a private placement of 936,066 common shares of par value KRW 500 to be issued at an issue price of KRW 10,683 per share for proceeds of KRW 9,999,993,078 on February 7, 2023. The transaction will include participation from returning investor CANARIABIO M Inc. The shares are to be issued pursuant to third party allotment method. The transaction is expected to close on February 15, 2023. The transaction has been approved by the board of directors. The securities will be subject to a hold period of one year.Price Target Changed • Nov 29Price target decreased to ₩19,900Down from ₩29,600, the current price target is provided by 1 analyst. New target price is 51% above last closing price of ₩13,150. Stock is down 41% over the past year. The company posted a net loss per share of ₩1,753 last year.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공고 • Sep 19Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)공고 • Sep 07Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis)Helixmith announced topline results from a Phase 2A study in individuals with ALS (Amyotrophic Lateral Sclerosis). ALS is a fatal neurodegenerative disorder of upper and lower motor neurons that causes progressive paralysis and eventual death due to respiratory failure. This Phase 2A was a double-blind placebo controlled multi-center study involving 5 sites (4 in the US and 1 in Korea) and 18 subjects randomized to a 2:1 ratio of Engensis to placebo. In this Phase 2A study, three treatments of Engensis, a plasmid DNA encoding human HGF, or placebo were injected in the upper and lower limbs on months 0, 2 and 4. One treatment consisted of two cycles of injections, on 2-week intervals, of 64 mg of Engensis or placebo in total. Therefore, a total of 192 mg of Engensis was given to each subject over a 4-month period. In addition, there was a follow-up period of 6 months after the first injection on Day 0. The results of the study demonstrated that Engensis was safe and well tolerated at this dosing regimen. There was no difference in the frequency of TEAEs (83% for each group) between the Engensis and the placebo groups. One TEAE, bronchitis, was reported in the Engensis group but was determined to not be related to the study drug. Injection site reactions were reported by 50% of the Engensis group and by 66.7% of the placebo group. Most of the injection site reactions were Grade 1 or 2 and resolved within a short time, and none of the participants in the study discontinued due to the number of injections. These data suggest that high dose, repeated treatments of Engensis, were safe and well tolerated, providing a great deal of flexibility in designing dosing schemes for future clinical studies. Given the primary endpoint of this study was to test safety and tolerability, efficacy was measured only as an exploratory parameter. ALSFRS-R scores, muscle functions using handheld dynamometry, and ALSAQ-40 were among the measurements collected. Since the study size was small and 4 subjects dropped out early, the company were unable to compare efficacy between the Engensis and placebo groups. An important component of this study was the collection of biopsy samples from the participants' injections sites. Engensis is an intramuscularly delivered gene therapy. The bulk of the data collected to date, showing effects of HGF expressed from Engensis, has been from animal models. Data collected from clinical trials has been limited thus far. Thanks to dedicated clinical trial participants, muscle biopsy samples were collected during the course of the trial and will be subjected to histological and molecular biological analyses using RNA-Seq. Helixmith greatly appreciates the generous and eager participation of the ALS patients. Data from these results are expected to provide valuable information on the understanding of the mechanisms of actions of Engensis, and its effects on the expression of human genes, which will greatly help in the development of innovative medicines based on HGF/c-Met signaling. Helixmith will continue the analysis of the Phase 2A data upon the receipt of the full report and plan to present results at a future conference and determine next steps for Engensis in ALS at that time.공고 • Aug 04Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19Helixmith announced topline results from the double-blind placebo controlled multicenter study for TADIOS involving one hundred subjects infected with COVID-19. This study was conducted in India in compliance with AYUSH guidelines. TADIOS is Helixmith's proprietary botanical formulation composed of three plants, which has been developed for the treatment of respiratory disease caused by viruses, microdust, and such. The primary goal of this study was to evaluate safety and tolerability of TADIOS, as well as its effects on efficacy parameters, which included biomarkers and clinical symptoms. Subjects diagnosed with COVID-19 infection, showing mild to moderate symptoms, were enrolled according to the clinical management guidelines of the Government of India. Subjects were randomized to TADIOS and placebo with a 1:1 ratio in which fifty patients were assigned in each group. TADIOS and placebo were administered in addition to the standard of care in a double-blinded manner. Efficacy parameters were measured after the 10-day treatment maximum per COVID-19 treatment guideline of India. Safety was assessed at 14-day follow up after treatment was completed. TADIOS was determined to be safe and well tolerated. The TADIOS treated group did not show any difference in adverse events compared to the placebo group, confirming its potential to be developed as a safe botanical treatment for COVID-19 treatment. In terms of efficacy, IL-1RA biomarker showed a statistically significant difference and improvement was demonstrated in one of the fatigue-related questionnaires. IL-1RA levels were higher by more than 3-fold in both groups, but the TADIOS treatment group showed a lower level at 2 weeks after the end of administration, compared to the placebo group (p<0.05). It has been reported that IL-1RA is maintained at elevated levels in blood during COVID-19 infection, and its level has a close correlation with the severity and mortality of infection. While known to regulate excessive inflammation, it is also present at elevated levels in a variety of pathologic conditions, such as obesity and rheumatoid arthritis, as well as at the severe stage of COVID-19 infection. Therefore, reduction of IR-1RA by taking TADIOS suggests its possibility of preventing or inhibiting the progression of symptoms caused by COVID-19 infection to severe illness. Among the six biomarkers measured, serum levels of CRP, ferritin, TNF-a and the level of hemoglobin in whole blood were all within the normal range in both groups. and no difference was shown between the two groups. TADIOS showed some improvement in fatigue, a common symptom in individuals with COVID-19 infections. In one of the questionnaires testing "I am easily fatigued," TADIOS-administered subjects showed statistically significant improvement vs placebo group, two weeks after treatment (p<0.05). Helixmith is planning to present full data at either an academic conference or in a journal publication upon the completion of the analysis.Reported Earnings • May 26First quarter 2022 earnings released: ₩335 loss per share (vs ₩92.65 profit in 1Q 2021)First quarter 2022 results: ₩335 loss per share (down from ₩92.65 profit in 1Q 2021). Net loss: ₩12.6b (down ₩15.3b from profit in 1Q 2021). Over the next year, revenue is expected to shrink by 16% compared to a 25% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 28Price target increased to ₩29,182Up from ₩26,529, the current price target is provided by 1 analyst. New target price is 44% above last closing price of ₩20,200. Stock is down 27% over the past year. The company posted a net loss per share of ₩1,753 last year.Price Target Changed • Apr 27Price target decreased to ₩26,529Down from ₩29,182, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₩20,150. Stock is down 29% over the past year. The company posted a net loss per share of ₩1,753 last year.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Price Target Changed • Dec 29Price target decreased to ₩26,529Down from ₩32,100, the current price target is provided by 1 analyst. New target price is 19% above last closing price of ₩22,350. Stock is down 26% over the past year. The company posted a net loss per share of ₩3,094 last year.공고 • Dec 02Helixmith Announces 50% Enrollment in Clinical Trial for COVID-19, Involving TADIOSHelixmith Co. Ltd. has announced that 50 subjects have been enrolled in its double-blind placebo controlled COVID-19 clinical trial involving 100 subjects. The investigational product is called TADIOS, which is a proprietary botanical treatment. The clinical trial is being conducted in India in accordance with the regulations of the Ministry of AYUSH, India's traditional medicine regulatory body. India has a high rate of COVID-19 infection and unmet medical need. The ongoing TADIOS clinical trial is being conducted in four trial sites. The trial is targeting patients diagnosed with COVID-19 who have mild to moderate clinical symptoms. Patients are being randomized 1:1, 50 subjects to the TADIOS group and 50 to the placebo group. TADIOS is being orally administered as an adjuvant to the COVID-19 standard treatment regimen under double-blinded conditions, and its efficacy and safety are assessed at 10 days and 14 days after administration. Various biochemical indicators, such as TNF-alpha, CRP, IL-6, IL-1Ra, Hb, and ferritin, are being measured at 10 days post administration or at the time of discharge, if earlier than 10 days. Anti-inflammatory and anti-oxidative activities are also being assessed. Clinical symptom improvement is determined using an 8-point sequence scale designed by the WHO. Quality of life, fatigue, and hospitalization periods are also evaluated. In pre-clinical studies, TADIOS (HX110) has shown to significantly inhibit lung damage in an acute lung injury mouse model. The therapeutic effects appeared to result from the control of excessive production of inflammatory and oxidative molecules such as TNF-a, IL-6, IL-1ß and ROS. The potential molecular mechanism underlying TADIOS' anti-inflammatory and anti-oxidative activities is its control of the Nrf2-HO-1 pathway. Thus, TADIOS appears to prevent or inhibit disease progression upon viral infection through a reduction of inflammatory and oxidative response. The results of these studies were published in the Journal of Ethnopharmacology.Price Target Changed • Apr 16Price target decreased to ₩33,000Down from ₩48,697, the current price target is provided by 1 analyst. New target price is 29% above last closing price of ₩25,500. Stock is down 62% over the past year.Is New 90 Day High Low • Feb 24New 90-day low: ₩24,550The company is down 16% from its price of ₩29,200 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.분석 기사 • Feb 19Would Shareholders Who Purchased Helixmith's (KOSDAQ:084990) Stock Three Years Be Happy With The Share price Today?As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize with...공고 • Jan 23Helixmith Co., Ltd announced that it has received KRW 20 billion in fundingOn January 22, 2021, Helixmith Co., Ltd (KOSDAQ:A084990) closed the transaction.공고 • Jan 22Helixmith Co., Ltd announced that it expects to receive KRW 20 billion in fundingHelixmith Co., Ltd (KOSDAQ:A084990) announced a private placement of 4th series unregistered non-guaranteed private convertible bonds for gross proceeds of KRW 20,000,000,000 on January 20, 2021. The transaction will include participation from new investor, Japan-made New Bio Fund. The bond is issued at 0% coupon rate and will mature on January 22, 2026. The bonds are 100% converted into 657,527 common shares representing 1.92% stake at a fixed conversion price of KRW 30,417 per share. The conversion period is from January 22, 2022 to December 22, 2025. The transaction has been approved by the board of directors of the company. The subscription date is January 20, 2021 and payment date is January 22, 2021.공고 • Dec 23Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion.Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,500,000 Price\Range: KRW 21500 Discount Per Security: KRW 322.5 Transaction Features: Rights OfferingIs New 90 Day High Low • Oct 16New 90-day low: ₩30,750The company is down 48% from its price of ₩58,800 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.공고 • Oct 06Helixmith to Be Deleted from Other OTCHelixmith Co., Ltd’s Ordinary Shares will be deleted from Other OTC effective September 29, 2020. The deletion is due to Inactive Security.Is New 90 Day High Low • Sep 18New 90-day low: ₩41,800The company is down 35% from its price of ₩64,500 on 19 June 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A084990 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A084990 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Helixmith 배당 수익률 vs 시장A084990의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A084990)n/a시장 하위 25% (KR)1.4%시장 상위 25% (KR)4.4%업계 평균 (Biotechs)0.5%분석가 예측 (A084990) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A084990 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A084990 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A084990 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A084990 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/14 16:04종가2026/07/14 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Helixmith Co., Ltd는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sangsoo KimGoldman SachsJaeik KimiM SecuritiesWan KuNH Investment & Securities Co., Ltd.1명의 분석가 더 보기
분석 기사 • 16hWe Think Helixmith (KOSDAQ:084990) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Apr 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (₩2.6b revenue, or US$1.7m).
분석 기사 • Mar 27We're Not Very Worried About Helixmith's (KOSDAQ:084990) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Helixmith ( KOSDAQ:084990...
공고 • Mar 13Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South Korea
New Risk • Sep 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Revenue is less than US$5m (₩5.0b revenue, or US$3.6m).
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (26% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change).
New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₩5.1b revenue, or US$3.7m).
분석 기사 • Jul 14We Think Helixmith (KOSDAQ:084990) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Mar 18Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
공고 • Mar 13Helixmith Co., Ltd, Annual General Meeting, Mar 27, 2025Helixmith Co., Ltd, Annual General Meeting, Mar 27, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South Korea
New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (₩127.3b market cap, or US$89.5m).
New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩140.0b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (₩3.2b revenue, or US$2.3m). Market cap is less than US$100m (₩140.0b market cap, or US$99.9m).
분석 기사 • Oct 18Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...
공고 • Apr 26Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in fundingOn April 25, 2024, Helixmith Co., Ltd closed the transaction.
공고 • Feb 06Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in fundingHelixmith Co., Ltd announced a private placement of 936,066 common shares at a price of KRW 3,610 per share for the gross proceeds of KRW 3,379,198,260 on February 5, 2024. The transaction has been approved by the shareholders of the company and is expected to close on April 25, 2024. The transaction will include participation from new investor, Woori Bank Magongnaru Station Branch.
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Revenue is less than US$5m (₩4.4b revenue, or US$3.4m).
공고 • Feb 09Helixmith Co., Ltd announced that it expects to receive KRW 9.999993078 billion in funding from CANARIABIO M Inc.Helixmith Co., Ltd announced a private placement of 936,066 common shares of par value KRW 500 to be issued at an issue price of KRW 10,683 per share for proceeds of KRW 9,999,993,078 on February 7, 2023. The transaction will include participation from returning investor CANARIABIO M Inc. The shares are to be issued pursuant to third party allotment method. The transaction is expected to close on February 15, 2023. The transaction has been approved by the board of directors. The securities will be subject to a hold period of one year.
Price Target Changed • Nov 29Price target decreased to ₩19,900Down from ₩29,600, the current price target is provided by 1 analyst. New target price is 51% above last closing price of ₩13,150. Stock is down 41% over the past year. The company posted a net loss per share of ₩1,753 last year.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공고 • Sep 19Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)
공고 • Sep 07Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis)Helixmith announced topline results from a Phase 2A study in individuals with ALS (Amyotrophic Lateral Sclerosis). ALS is a fatal neurodegenerative disorder of upper and lower motor neurons that causes progressive paralysis and eventual death due to respiratory failure. This Phase 2A was a double-blind placebo controlled multi-center study involving 5 sites (4 in the US and 1 in Korea) and 18 subjects randomized to a 2:1 ratio of Engensis to placebo. In this Phase 2A study, three treatments of Engensis, a plasmid DNA encoding human HGF, or placebo were injected in the upper and lower limbs on months 0, 2 and 4. One treatment consisted of two cycles of injections, on 2-week intervals, of 64 mg of Engensis or placebo in total. Therefore, a total of 192 mg of Engensis was given to each subject over a 4-month period. In addition, there was a follow-up period of 6 months after the first injection on Day 0. The results of the study demonstrated that Engensis was safe and well tolerated at this dosing regimen. There was no difference in the frequency of TEAEs (83% for each group) between the Engensis and the placebo groups. One TEAE, bronchitis, was reported in the Engensis group but was determined to not be related to the study drug. Injection site reactions were reported by 50% of the Engensis group and by 66.7% of the placebo group. Most of the injection site reactions were Grade 1 or 2 and resolved within a short time, and none of the participants in the study discontinued due to the number of injections. These data suggest that high dose, repeated treatments of Engensis, were safe and well tolerated, providing a great deal of flexibility in designing dosing schemes for future clinical studies. Given the primary endpoint of this study was to test safety and tolerability, efficacy was measured only as an exploratory parameter. ALSFRS-R scores, muscle functions using handheld dynamometry, and ALSAQ-40 were among the measurements collected. Since the study size was small and 4 subjects dropped out early, the company were unable to compare efficacy between the Engensis and placebo groups. An important component of this study was the collection of biopsy samples from the participants' injections sites. Engensis is an intramuscularly delivered gene therapy. The bulk of the data collected to date, showing effects of HGF expressed from Engensis, has been from animal models. Data collected from clinical trials has been limited thus far. Thanks to dedicated clinical trial participants, muscle biopsy samples were collected during the course of the trial and will be subjected to histological and molecular biological analyses using RNA-Seq. Helixmith greatly appreciates the generous and eager participation of the ALS patients. Data from these results are expected to provide valuable information on the understanding of the mechanisms of actions of Engensis, and its effects on the expression of human genes, which will greatly help in the development of innovative medicines based on HGF/c-Met signaling. Helixmith will continue the analysis of the Phase 2A data upon the receipt of the full report and plan to present results at a future conference and determine next steps for Engensis in ALS at that time.
공고 • Aug 04Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19Helixmith announced topline results from the double-blind placebo controlled multicenter study for TADIOS involving one hundred subjects infected with COVID-19. This study was conducted in India in compliance with AYUSH guidelines. TADIOS is Helixmith's proprietary botanical formulation composed of three plants, which has been developed for the treatment of respiratory disease caused by viruses, microdust, and such. The primary goal of this study was to evaluate safety and tolerability of TADIOS, as well as its effects on efficacy parameters, which included biomarkers and clinical symptoms. Subjects diagnosed with COVID-19 infection, showing mild to moderate symptoms, were enrolled according to the clinical management guidelines of the Government of India. Subjects were randomized to TADIOS and placebo with a 1:1 ratio in which fifty patients were assigned in each group. TADIOS and placebo were administered in addition to the standard of care in a double-blinded manner. Efficacy parameters were measured after the 10-day treatment maximum per COVID-19 treatment guideline of India. Safety was assessed at 14-day follow up after treatment was completed. TADIOS was determined to be safe and well tolerated. The TADIOS treated group did not show any difference in adverse events compared to the placebo group, confirming its potential to be developed as a safe botanical treatment for COVID-19 treatment. In terms of efficacy, IL-1RA biomarker showed a statistically significant difference and improvement was demonstrated in one of the fatigue-related questionnaires. IL-1RA levels were higher by more than 3-fold in both groups, but the TADIOS treatment group showed a lower level at 2 weeks after the end of administration, compared to the placebo group (p<0.05). It has been reported that IL-1RA is maintained at elevated levels in blood during COVID-19 infection, and its level has a close correlation with the severity and mortality of infection. While known to regulate excessive inflammation, it is also present at elevated levels in a variety of pathologic conditions, such as obesity and rheumatoid arthritis, as well as at the severe stage of COVID-19 infection. Therefore, reduction of IR-1RA by taking TADIOS suggests its possibility of preventing or inhibiting the progression of symptoms caused by COVID-19 infection to severe illness. Among the six biomarkers measured, serum levels of CRP, ferritin, TNF-a and the level of hemoglobin in whole blood were all within the normal range in both groups. and no difference was shown between the two groups. TADIOS showed some improvement in fatigue, a common symptom in individuals with COVID-19 infections. In one of the questionnaires testing "I am easily fatigued," TADIOS-administered subjects showed statistically significant improvement vs placebo group, two weeks after treatment (p<0.05). Helixmith is planning to present full data at either an academic conference or in a journal publication upon the completion of the analysis.
Reported Earnings • May 26First quarter 2022 earnings released: ₩335 loss per share (vs ₩92.65 profit in 1Q 2021)First quarter 2022 results: ₩335 loss per share (down from ₩92.65 profit in 1Q 2021). Net loss: ₩12.6b (down ₩15.3b from profit in 1Q 2021). Over the next year, revenue is expected to shrink by 16% compared to a 25% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 28Price target increased to ₩29,182Up from ₩26,529, the current price target is provided by 1 analyst. New target price is 44% above last closing price of ₩20,200. Stock is down 27% over the past year. The company posted a net loss per share of ₩1,753 last year.
Price Target Changed • Apr 27Price target decreased to ₩26,529Down from ₩29,182, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₩20,150. Stock is down 29% over the past year. The company posted a net loss per share of ₩1,753 last year.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Price Target Changed • Dec 29Price target decreased to ₩26,529Down from ₩32,100, the current price target is provided by 1 analyst. New target price is 19% above last closing price of ₩22,350. Stock is down 26% over the past year. The company posted a net loss per share of ₩3,094 last year.
공고 • Dec 02Helixmith Announces 50% Enrollment in Clinical Trial for COVID-19, Involving TADIOSHelixmith Co. Ltd. has announced that 50 subjects have been enrolled in its double-blind placebo controlled COVID-19 clinical trial involving 100 subjects. The investigational product is called TADIOS, which is a proprietary botanical treatment. The clinical trial is being conducted in India in accordance with the regulations of the Ministry of AYUSH, India's traditional medicine regulatory body. India has a high rate of COVID-19 infection and unmet medical need. The ongoing TADIOS clinical trial is being conducted in four trial sites. The trial is targeting patients diagnosed with COVID-19 who have mild to moderate clinical symptoms. Patients are being randomized 1:1, 50 subjects to the TADIOS group and 50 to the placebo group. TADIOS is being orally administered as an adjuvant to the COVID-19 standard treatment regimen under double-blinded conditions, and its efficacy and safety are assessed at 10 days and 14 days after administration. Various biochemical indicators, such as TNF-alpha, CRP, IL-6, IL-1Ra, Hb, and ferritin, are being measured at 10 days post administration or at the time of discharge, if earlier than 10 days. Anti-inflammatory and anti-oxidative activities are also being assessed. Clinical symptom improvement is determined using an 8-point sequence scale designed by the WHO. Quality of life, fatigue, and hospitalization periods are also evaluated. In pre-clinical studies, TADIOS (HX110) has shown to significantly inhibit lung damage in an acute lung injury mouse model. The therapeutic effects appeared to result from the control of excessive production of inflammatory and oxidative molecules such as TNF-a, IL-6, IL-1ß and ROS. The potential molecular mechanism underlying TADIOS' anti-inflammatory and anti-oxidative activities is its control of the Nrf2-HO-1 pathway. Thus, TADIOS appears to prevent or inhibit disease progression upon viral infection through a reduction of inflammatory and oxidative response. The results of these studies were published in the Journal of Ethnopharmacology.
Price Target Changed • Apr 16Price target decreased to ₩33,000Down from ₩48,697, the current price target is provided by 1 analyst. New target price is 29% above last closing price of ₩25,500. Stock is down 62% over the past year.
Is New 90 Day High Low • Feb 24New 90-day low: ₩24,550The company is down 16% from its price of ₩29,200 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.
분석 기사 • Feb 19Would Shareholders Who Purchased Helixmith's (KOSDAQ:084990) Stock Three Years Be Happy With The Share price Today?As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize with...
공고 • Jan 23Helixmith Co., Ltd announced that it has received KRW 20 billion in fundingOn January 22, 2021, Helixmith Co., Ltd (KOSDAQ:A084990) closed the transaction.
공고 • Jan 22Helixmith Co., Ltd announced that it expects to receive KRW 20 billion in fundingHelixmith Co., Ltd (KOSDAQ:A084990) announced a private placement of 4th series unregistered non-guaranteed private convertible bonds for gross proceeds of KRW 20,000,000,000 on January 20, 2021. The transaction will include participation from new investor, Japan-made New Bio Fund. The bond is issued at 0% coupon rate and will mature on January 22, 2026. The bonds are 100% converted into 657,527 common shares representing 1.92% stake at a fixed conversion price of KRW 30,417 per share. The conversion period is from January 22, 2022 to December 22, 2025. The transaction has been approved by the board of directors of the company. The subscription date is January 20, 2021 and payment date is January 22, 2021.
공고 • Dec 23Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion.Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,500,000 Price\Range: KRW 21500 Discount Per Security: KRW 322.5 Transaction Features: Rights Offering
Is New 90 Day High Low • Oct 16New 90-day low: ₩30,750The company is down 48% from its price of ₩58,800 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
공고 • Oct 06Helixmith to Be Deleted from Other OTCHelixmith Co., Ltd’s Ordinary Shares will be deleted from Other OTC effective September 29, 2020. The deletion is due to Inactive Security.
Is New 90 Day High Low • Sep 18New 90-day low: ₩41,800The company is down 35% from its price of ₩64,500 on 19 June 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.